You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services.
Pfizer has been the second-best-performing big pharma stock for the whole of 2021.
Pfizer’s shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antiviral pill Paxlovid.
Comirnaty is slated to haul in no less than $36 billion in sales in 2021.
During Pfizer’s third-quarter earnings presentation, management said that Comirnaty is already on track to rake in $29 billion in sales in 2022.
With demand for COVID vaccines likely to remain at fever pitch next year and Pfizer/BioNtech already hard at work designing an omicron-specific formulation, this dynamic duo might post another year of record-breaking vaccine sales in 2022.
While its vaccine sales should continue to be stellar in 2022, the company will almost certainly get another major boost from its oral coronavirus pill Paxlovid.
And since onboarding Malik, Pfizer’s brain trust has openly admitted that it is on the hunt for intriguing phase 2 and phase 3 assets to keep the growth train rolling in the second half of the decade.
While the company hasn’t seemed inclined to go the megamerger route since its failed pursuit of Allergan a few years back, there are some good reasons to believe that one may be close at hand.
Pfizer’s stock presently comes with a 3% annualized dividend yield, which is slightly above average for its peer group.
On top of its strong dividend program, the company also has over $5 billion remaining under its current share repurchase program.